ArticleFrontiers in medicine2026
Herbal medicine as a complementary therapy for dysmenorrhea: effects on pain and reduction of analgesic use.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Dysmenorrhea is a prevalent gynecological disorder impairing quality of life for women of reproductive age. Although traditional herbal decoctions (THDs) are widely used for dysmenorrhea in Korea, robust real-world evidence regarding their clinical outcomes and safety is limited. This descriptive, hypothesis-generating registry study aimed to examine individualized THDs for dysmenorrhea using registry data from a multicenter observational study. Methods: This multicenter, prospective observational registry study enrolled women aged 19-65 years with dysmenorrhea from 33 traditional Korean medicine (TKM) clinics and one TKM hospital in Korea (July 2022-June 2023). Participants were categorized into a THD group (received THDs for ≥10 days) and a non-THD group. Primary outcomes were changes in pain intensity (Numeric Rating Scale, NRS), duration of menstrual pain, and analgesic consumption (defined as the number of analgesic tablets taken per menstrual cycle), assessed at each visit. To address confounding and selection bias, a difference-in-differences analysis using inverse probability of treatment weighting (IPTW) based on propensity scores was performed. Missing data were handled using complete-case analysis, supported by Little's MCAR test ( Results: A total of 119 participants in the THD group and 16 in the non-THD group completed the study. Both groups demonstrated significant within-group reductions in menstrual pain intensity over time. Regarding between-group differences, the THD group showed a significantly greater observed reduction in menstrual pain intensity at visit 2 compared to the non-THD group (Estimate = -1.41, Conclusion: These preliminary findings suggest that individualized THDs may be associated with reduced menstrual pain intensity and analgesic consumption in women with dysmenorrhea in real-world settings; however, significant between-group differences were observed at a single time point only, pain duration did not differ significantly between groups, and comparative safety conclusions remain constrained by the small control group. Larger, adequately powered studies are needed to confirm these exploratory findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.